The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States

J. Bradford Rice, Alan G. White, Philip Galebach, Kevin M. Korenblat, Aneesha Wagh, Belinda Lovelace, George J. Wan, Khurram Jamil

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: This study evaluated the characteristics, healthcare resource utilization (HCRU), and costs, from the payer perspective, of hepatorenal syndrome (HRS) patients covered by commercial and Medicare insurance. Mortality was assessed as a secondary outcome. Methods: Patients were identified from claims databases of commercially insured patients (OptumHealth Care Solutions Inc.) in 1998–2014 and Medicare beneficiaries in 2009–2013 (5% Standard Analytic Files). At the time of their first inpatient admission (“index date”) with an HRS diagnosis (ICD-9 code 572.4), commercially insured patients must be aged 18–64 and Medicare patients must be aged 65 and older. Results: A total of 784 commercially insured and 1061 Medicare HRS patients met the sample selection criteria. Patients were disproportionately male (commercial: 63.0%; Medicare: 57.9%) with a mean age of 54.1 among commercially insured and 74.1 among Medicare patients. Within the first 30 days, the average hospital length of stay (LOS) was 12.3 days among commercially insured and 10.8 days among Medicare patients. Based on Kaplan–Meier analyses, 36% of commercially insured and 26% of Medicare patients were readmitted within the next 30 days. During follow-up, many patients received dialysis (commercial: 33.0%; Medicare: 22.1%) or liver transplant (commercial: 10.7%; Medicare: 1.6%). Average costs within the 90 day follow-up were $157,665 for commercially insured and $48,322 for Medicare patients, with 68.3% and 78.3% of the costs incurred within the first 30 days. The primary cost driver was inpatient visits (commercial: 90.3% of costs; Medicare: 83.1% of costs), with differences between the populations consistent with lower mortality, higher dialysis rates, and higher transplant rates (both liver and kidney) among the commercially insured. Using US population and prevalence statistics, these results suggest that HRS imposes an annual total direct medical cost burden of approximately $3.0–$3.8 billion to payers over the period. Conclusions: HRS imposes a significant economic burden.

Original languageEnglish
Pages (from-to)1473-1480
Number of pages8
JournalCurrent Medical Research and Opinion
Issue number8
StatePublished - Aug 3 2017


  • Hepatorenal syndrome
  • administrative claims
  • burden
  • payer burden


Dive into the research topics of 'The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States'. Together they form a unique fingerprint.

Cite this